Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 19Terminated 4Unknown 2Active not recruiting 2Withdrawn 1Suspended 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Burkitt Lymphoma 2Triple Negative Breast Neoplasms 1Prostate Cancer Recurrent 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Blast Crisis 1

Interventions

venetoclax 22Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4Dexamethasone 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2Mycophenolic Acid 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia × Dasatinib × Clear all
NCT05751044 2025-09-16

HEM-iSMART B

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡